Join the Tecvayli group to help and get support from people like you.
Tecvayli News
Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma
WEDNESDAY, July 16, 2025 – In a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a T-cell-engaging bispecific antibody that targets...
Talquetamab Plus Teclistamab Shows Promise in Multiple Myeloma
THURSDAY, Jan. 9, 2025 – For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or...
Tecvayli (teclistamab-cqyv) Biweekly Dosing Approved by the U.S. FDA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., Feb. 20, 2024 /PRNewswire/ – Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...
FDA Approves Tecvayli (teclistamab-cqyv) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Tecvayli, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options HORSHAM, Pa., October 25, 2022 – The J...